Electrogenics Laboratories Limited

Electrogenics Laboratories Limited is a health care startup founded in 2019 and headquartered in Australia. The company has developed the next generation MOSkin dosimeter, a breakthrough medical radiation sensor technology that accurately measures individual radiation doses and dose rates in real time for the global $35 billion radiotherapy for cancer treatment, angiography equipment and CT and X-ray scan markets. This patented technology, developed by the Centre for Medical Radiation Physics at the University of Wollongong, Australia, has been fully tested and proven with over $8 million of grant funding in over 20 hospitals and clinics worldwide, including Australia, Brazil, Italy, Malaysia, and China. The senior management and support staff team at ELL boasts extensive experience in advanced technology product development and international business development, positioning the company to rapidly drive MOSkin to full global commercialization and distribution. Distinguished Professor Anatoly Rozenfeld, Professor Michael Lerch, and Associate Professor Marco Petasecca from the University of Wollongong are ELL’s scientific advisors, and the company collaborates with Australian development partners including Genesys Electronics Design and Design & Industry. With a mission to become the world leader in the development and provision of cutting edge, next-generation radiation dosimetry solutions, Electrogenics Laboratories Limited is poised to contribute significantly to the advancement of medical radiation technology.